Biotech Avrobio plans head-to-head Fabrazyme trial after FDA changes path to market

Avrobio has updated its Fabry disease gene therapy R&D plans in light of the FDA’s conversion of Sanofi’s Fabrazyme to full approval. The conversion deprives Avrobio of the chance to seek accelerated approval using its current phase 2, leading the biotech to plan to pit AVR-RD-01 against Fabrazyme in a new head-to-head clinical trial.